2[3]Curtis JJ. Differences in bioavailability between oral cyclosporine formulations in maintenance renal transplant patients filiation. Am J Kidney Dis, 1999, 34(5): 869 被引量：1
3[4]Min DI. Bioavailability and patient acceptance of cyclosporine soft geltin capsules in renal allograft recipients. Ann Pharmacother, 1992,26(2): 175 被引量：1
4[5]Kovarik JM.Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy, 1993,13(6): 613 被引量：1
5[6]Sadler BM.Safety and pharmacokinetics of amprenavir (141W94),a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother, 1999,43(7): 1686 被引量：1
6[7]Hong SS. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J Control Release, 1998, 1251(2～3): 185 被引量：1
7[8]Takahashi M. Studies on dissolution tests for soft gelatin capsules by the rotating dialysis cell (RDC) method. Ⅵ.Preparation and evaluation of ibuprofen soft gelatin capsule. Chem Pharm Bull (Tokyo),1995,43(8): 1398 被引量：1
8[9]Takahashi M. Studies on dissolution tests for soft gelatin capsules. Ⅳ. Dissolution test of nifedipine soft gelatin capsule containing water soluble vehicles by the rotating dialysis cell method. Chem Pharm Bull (Tokyo),1994,42(2): 333 被引量：1
9[10]Amemiya T. Emulsion type new vehicle for soft gelatin capsule available for preclinical and clinical trials: effects of PEG 6000 and PVP K30 on physicochemical stability of new vehicle. Chem Pharm Bull (Tokyo),1999,47(4): 492 被引量：1
10[11]Amemiya T. Development of emulsion type new vehicle for soft gelatin capsule. I. Selection of surfactants for development of new vehicle and its physicochemical properties. Chem Pharm Bull (Tokyo),1998,46(2): 309 被引量：1
